Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biology and Time Course of Obstruction-Induced Detrusor Underactivity Causing Postvoid Residual Urine.

International neurourology journal·2026
Same author

Bladder under stress: Pathological and adaptive shifts in channel expression.

Channels (Austin, Tex.)·2026
Same author

Erectile and Clitoral Dysfunction as Harbingers of Cardiovascular Disease: A Perspective.

Medicina (Kaunas, Lithuania)·2026
Same author

Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia.

Continence (Amsterdam, Netherlands)·2026
Same author

Urethral pharmacological mechanisms incontinence and bladder emptying: An updated review.

Bladder (San Francisco, Calif.)·2024
Same author

Cellular regenerative therapy in stress urinary incontinence: new frontiers?-a narrative review.

Translational andrology and urology·2024

Related Experiment Video

Updated: May 30, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Therapeutic targets for premature ejaculation.

Karl-Erik Andersson1, Ibrahim A Abdel-Hamid

  • 1Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston Salem, NC 27157, USA. keanders@wfubmc.edu

Maturitas
|August 6, 2011
PubMed
Summary

Premature ejaculation (PE) is a common male sexual complaint. Research is exploring new therapeutic targets in the brain and penis to improve long-term PE treatment success.

Area of Science:

  • Urology
  • Neuroscience
  • Pharmacology

Background:

  • Premature ejaculation (PE) is the most frequent male sexual dysfunction, significantly impacting quality of life.
  • Current treatments, including selective serotonin reuptake inhibitors (SSRIs) and topical agents, offer limited long-term efficacy.
  • Dapoxetine, a short-acting SSRI, is the only approved PE treatment, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To review current and potential therapeutic targets for premature ejaculation (PE).
  • To analyze the roles of various central and peripheral targets in PE pathophysiology.
  • To guide future research for developing more effective PE treatments.

Main Methods:

  • Literature review of central nervous system (CNS) and peripheral targets implicated in PE.

Related Experiment Videos

Last Updated: May 30, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

  • Discussion of neurotransmitter systems (serotonin, dopamine, oxytocin, opioids) and other molecular pathways.
  • Analysis of adrenoceptors, phosphodiesterase enzymes, Rho kinases, purinergic receptors, and penile nerves.

    • Main Results:

    • Identified multiple potential CNS targets, including serotonin transporters (SERT), 5-HT(1A), 5-HT(1B), dopamine, oxytocin, opioid, neurokinin-1, and glutamate receptors.
    • Highlighted peripheral targets such as α(1)-adrenoceptors, phosphodiesterase (PDE) enzymes, Rho kinases, P2X receptors, and penile sensory nerves.
    • Emphasized the complex pathophysiology of PE involving diverse neurochemical and physiological pathways.

    Conclusions:

    • Numerous promising therapeutic targets exist for PE, both centrally and peripherally.
    • Further basic and clinical research is essential to fully understand and exploit these targets for improved PE management.
    • Developing novel treatments requires a deeper understanding of PE pathophysiology and target-specific drug development.